主页 > 医学动态 >
【drug-news】FDA 顾问委员会认可长效Zyprexa
FDA Panel Says Long-Acting Zyprexa is Worth the Risk
Posted by Jacob Goldstein
Eli Lilly may still be in hot water over its marketing of Zyprexa, but the company got a bit of Zyprexa-related good news this afternoon. A committee of FDA advisers said the agency should approve the company’s long-acting version of the drug for use in some patients.
The committee voted unanimously that long-acting Zyprexa is effective at treating schizophrenia, Dow Jones Newswires reports. But the members shared the concerns of an FDA staffer who noted that the drug caused profound sedation for a few hours in some patients. The panel said the injected form of the drug should be reserved for patients with a history of not taking their pills.
The current form of the drug is a once-a-day pill. The injectable version would be given by a doctor every two or four weeks.
The patent on regular Zyprexa is set to expire in 2011. Drug companies often introduce long-acting versions of drugs shortly before the patent on the original is set to expire, in order to compete against generics. [标签:content1][标签:content2]
阅读本文的人还阅读：
作者:admin@医学,生命科学 2011-03-25 15:22
医学,生命科学网